Search

Displaying results 7261 - 7270 of 10000 in total
  1. Indication

    Suppurative Otitis Media

    go.drugbank.com/conditions/DBCOND0107024
    Drugs: Ciprofloxacin
    Synonyms: Purulent otitis media NOS, Purulent otitis media, NOS
  2. Indication

    Anterior Uveitis

    go.drugbank.com/conditions/DBCOND0031055
    Drugs: Cyclopentolate · Difluprednate · Rimexolone
    Synonyms: Iridocyclitis, NOS, Anterior uveitis, NOS
  3. Indication

    Gingivitis

    go.drugbank.com/conditions/DBCOND0010261
    Drugs: Amylmetacresol · Benzalkonium · Benzamidine · Benzocaine · Benzydamine · Cetylpyridinium +9 more
    Synonyms: Gingivitis, NOS, Chronic gingivitis NOS (disorder)
  4. Drug

    Renzapride

    go.drugbank.com/drugs/DB04917
    Investigational

    It is being developed by Alizyme of the UK.

  5. Drug

    Bizalimogene ralaplasmid

    go.drugbank.com/drugs/DB16113
    Investigational

    Bizalimogene ralaplasmid is under investigation in clinical trial NCT03499795 (VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 And/or HPV-18 Related

  6. Drug

    Eflepedocokin alfa

    go.drugbank.com/drugs/DB16366
    Investigational

    [A225706, L27661] It is being developed by Evive Biotech (previously known as Generon BioMed Inc).[L27666]

  7. Drug

    OTL-201

    go.drugbank.com/drugs/DB17652
    Experimental

    OTL-201 is an investigational hematopoietic stem cell (HSC) gene therapy being developed by Orchard Therapeutics for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA). … It consists of a lentiviral vector to insert a functional copy of the human N-Sulfoglucosamine Sulfohydrolase (SGSH) gene into autologous CD34+ hematopoietic stem cells.[L45973]

  8. Drug

    Tavilermide

    go.drugbank.com/drugs/DB12441
    Investigational

    Tavilermide has been investigated for the treatment of Dry Eye Syndromes.

  9. Drug

    4'-Methylene-5,8,10-trideazaaminopterin

    go.drugbank.com/drugs/DB05616
    Investigational

    CH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable antifolate that is more efficiently taken up into cells by the reduced folate carrier

  10. Drug

    MK-0354

    go.drugbank.com/drugs/DB05939
    Investigational

    MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders.